SCHEMBL3017652

SCHEMBL3017652

Cc1ccccc1Cc1csc(N2CCC(S(=O)(=O)c3cccc(Cl)c3)CC2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GRM5 P41594 1/20 0.35
POLB P06746 1/20 0.34
HTR6 P50406 1/20 0.34
HTR2A P28223 2/20 0.34
MAPT P10636 2/20 0.34
DNM1L O00429 2/20 0.34
CTPS1 P17812 2/20 0.34
GBA1 P04062 1/20 0.34
NPC1 O15118 1/20 0.34
F2 P00734 1/20 0.34
F2RL3 Q96RI0 1/20 0.34
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
CHRM4 P08173 1/20 0.33
HTR2C P28335 1/20 0.33
MAPK8 P45983 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3004586 0.94 RAB9A (0.40) RAB9ASMN1; SMN2GRM5POLBHTR6
SCHEMBL3012054 0.94 MAPT (0.35) RAB9ASMN1; SMN2HTR2AMAPTDNM1L
SCHEMBL3008920 0.91 RAB9A (0.38) RAB9ASMN1; SMN2GRM5POLBHTR6
SCHEMBL3001213 0.91 RAB9A (0.40) RAB9ASMN1; SMN2GRM5POLBHTR6
SCHEMBL3017650 0.91 GBA1 (0.39) RAB9ASMN1; SMN2HTR2AMAPTDNM1L
SCHEMBL3014505 0.89 SCN1A (0.36) SMN1; SMN2GRM5HTR6DNM1LGBA1
SCHEMBL3002356 0.89 GPR6 (0.40) RAB9ASMN1; SMN2GRM5HTR2AMAPT
SCHEMBL3017287 0.89 DNM1L (0.34) RAB9AHTR2ADNM1LGBA1NPC1
SCHEMBL3001160 0.89 DRD2 (0.38) RAB9ASMN1; SMN2POLBHTR2AMAPT
SCHEMBL3007560 0.89 KDM1A (0.40) RAB9ASMN1; SMN2HTR6MAPTF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885SMN1; SMN2 1/4885GRM5 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.